Screening of nucleic acid aptamer of lung cancer cells based on cell exponential enrichment ligand system evolution and its application in tumor diagnosis and treatment_Journal of Biomedical Engineering

Authors：

XU Jinling , LIAO Shiqi , TIAN Caiping , ZHANG Lei , ZHAI Meng , CHEN Congying , TANG Jinzhou ,  ZENG Jiayu

Department of Biochemistry and Molecular Biology, College of Life Sciences of Northwest Normal University, Lanzhou 730070, P.R.China;

Corresponding author：

Keywords：

systematic evolution of ligands for cell exponential enrichment technology; aptamer; lung cancer cells; tumor diagnosis and treatment

DOI：

10.7507/1001-5515.201806006

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Nucleic acid aptamer is an oligonucleotide sequence screened by the exponential enrichment ligand system evolution technology (SELEX). Previous studies have shown that nucleic acid aptamer has a good application prospect in tumor diagnosis and treatment. Therefore, we reviewed the selection and identification of nucleic acid aptamer of lung cancer cells in recent years, and discussed the effect of aptamer as targeting drugs and targeting vectors on the diagnosis of tumors, which provide a new idea for early diagnosis and treatment of tumor.

Citation： XU Jinling, LIAO Shiqi, TIAN Caiping, ZHANG Lei, ZHAI Meng, CHEN Congying, TANG Jinzhou, ZENG Jiayu. Screening of nucleic acid aptamer of lung cancer cells based on cell exponential enrichment ligand system evolution and its application in tumor diagnosis and treatment. Journal of Biomedical Engineering, 2018, 35(6): 964-969. doi: 10.7507/1001-5515.201806006 Copy

1.	Chen Wanqing, Zheng Rongshou, Baade P D, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
2.	Gold L, Janjic N, Jarvis T, et al. Aptamers and the RNA world, past and present. Cold Spring Harb Perspect Biol, 2012, 4(3): 829-841.
3.	Mckeague M, Mcconnell E M, Cruz-Toledo J A, et al. Analysis of in vitro aptamer selection parameters. J Mol Evol, 2015, 81(5/6): 150-161.
4.	Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990, 249(4968): 505-510.
5.	Ellington A D, Szostak J W. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346(6287): 818-822.
6.	Chen Chan, Zhou Shan, Cai Yongqiang, et al. Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology. Npj Precision Oncology, 2017, 1(1): 37.
7.	Pang Xuehui, Cui Cheng, Wan Shuo, et al. Bioapplications of Cell-SELEX-generated aptamers in cancer diagnostics, therapeutics, theranostics and biomarker discovery: a comprehensive review. Cancers (Basel), 2018, 10(2): 47.
8.	Shangguan Dihua, Li Ying, Tang Zhiwen, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A, 2006, 103(32): 11838-11843.
9.	Quang N N, Miodek A, Cibiel A, et al. Selection of aptamers against whole living cells: from Cell-SELEX to identification of biomarkers. Synthetic Antibodies, 2017, 1575: 253-272.
10.	Dou Xiaoqian, Wang Hua, Zhang Jing, et al. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity. Int J Nanomedicine, 2018, 13: 763-776.
11.	Hori S I, Herrera A, Rossi J J, et al. Current advances in aptamers for cancer diagnosis and therapy. Cancers (Basel), 2018, 10(1): 9.
12.	Catuogno S, Esposito C L, de Franciscis V. Developing aptamers by cell-based SELEX. Methods in Molecular Biology, 2016, 1380: 33.
13.	吴巧艺. 基于 Cell-SELEX 胶质肉瘤与胶质瘤干细胞核酸适配体的筛选及初步应用研究. 福州: 福建医科大学, 2016.
14.	Wu Qiaoyi, Wang Yuzhe, Wang Hongyao, et al. DNA aptamers from whole-cell SELEX as new diagnostic agents against glioblastoma multiforme cells. Analyst, 2018, 143(10): 2267-2275.
15.	Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 2013, 63(1): 11-30.
16.	Chen H W, Medley C D, Sefah K, et al. Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem, 2008, 3(6): 991-1001.
17.	Kunii T, Ogura S I, Mie Masayasu, et al. Selection of DNA aptamers recognizing small cell lung cancer using living cell-SELEX. Analyst, 2011, 136(7): 1310-1312.
18.	Zhao Zilong, Xu Li, Shi Xiaoli, et al. Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. Analyst, 2009, 134(9): 1808-1814.
19.	Zamay G S, Kolovskaya O S, Zamay T N, et al. Aptamers selected to postoperative lung adenocarcinoma detect circulating tumor cells in human blood. Molecular Therapy, 2015, 23(9): 1486-1496.
20.	He Jinfeng, Tan Wei, Ma Jingping. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer. Future Oncology, 2017, 13(9): 787-797.
21.	Zamay G S, Ivanchenko T I, Zamay T N, et al. DNA aptamers for the characterization of histological structure of lung adenocarcinoma. Mol Ther Nucleic Acids, 2017, 6: 150-162.
22.	Wu Chunlei, Liu Jianbo, Zhang Pengfei, et al. A recognition-before-labeling strategy for sensitive detection of lung cancer cells with a quantum dot-aptamer complex. Analyst, 2015, 140(17): 6100-6107.
23.	李金明, 章志怀, 彭振元. SELEX 技术筛选特异性结合高转移性肺癌细胞 Anip973 的单链 DNA 适配子. 武汉大学学报: 医学版, 2011, 32(3): 329-333.
24.	Wang Qing, Zhou Chenchen, Yang Xiaohai, et al. Probing interactions between human lung adenocarcinoma A549 cell and its aptamers at single-molecule resolution. Journal of Molecular Recognition, 2014, 27(11): 676-682.
25.	Nabavinia M S, Charbgoo F, Alibolandi M, et al. Comparison of flow cytometry and ELASA for screening of proper candidate aptamer in Cell-SELEX pool. Appl Biochem Biotechnol, 2018, 184(2): 444-452.
26.	Sett A, Borthakur B B, Bora U. Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas. Clinical & Translational Oncology, 2017, 19(8): 976-988.
27.	Yuan Baoyin, Jiang Xiaochun, Chen Yuanyuan, et al. Metastatic cancer cell and tissue-specific fluorescence imaging using a new DNA aptamet developed by Cell-SELEX. Talanta, 2017, 170: 56-62.
28.	Ott W, Jobst M A, Schoeler C, et al. Single-molecule force spectroscopy on polyproteins and receptor-ligand complexes: The current toolbox. J Struct Biol, 2017, 197(1, SI): 3-12.
29.	Liu Lishang, Lu Xiaoling, Zhao Yongxiang. Aptamer-Based strategies for cancer diagnosis and therapy. J Nanosci Nanotechnol, 2016, 16(7): 6611-6621.
30.	Mackey D, Kelly E, Nooney R. Modelling random antibody adsorption and immunoassay activity. Mathematical Biosciences and Engineering, 2016, 13(6, SI): 1159-1168.
31.	Yin Meili, Li Zhenhua, Liu Zhen, et al. Photosensitizer-incorporated G-quadruplex DNA-functionalized magnetofluorescent nanoparticles for targeted magnetic resonance/fluorescence multimodal imaging and subsequent photodynamic therapy of cancer. Chemical Communications, 2012, 48(52): 6556-6558.
32.	Jin Cheng, Qiu Liping, Li Jin, et al. Cancer biomarker discovery using DNA aptamers. Analyst, 2016, 141(2): 461-466.
33.	Gold L, Ayers D, Bertino J, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One, 2010, 5(12): e15004.
34.	Havel L S, Kline E R, Salgueiro A M, et al. Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity. Oncogene, 2015, 34(15): 1979-1990.
35.	Almasi F, Gargari S M, Bitaraf F, et al. Development of a single stranded DNA aptamer as a molecular probe for LNCap cells using Cell-SELEX. Avicenna J Med Biotechnol, 2016, 8(3): 104-111.
36.	Lai Weiyun, Wang Weiya, Chang Y C, et al. Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras. Biomaterials, 2014, 35(9): 2905-2914.
37.	Perepelyuk M, Sacko K, Thangavel K, et al. Evaluation of MUC1-aptamer functionalized hybrid nanoparticles for targeted delivery of miRNA-29b to non-small cell lung cancer. Molecular Pharmaceutics, 2018, 15(3): 985-993.
38.	Morita Y, Leslie M, Kameyama H, et al. Aptamer therapeutics in cancer: current and future. Cancers (Basel), 2018, 10(3): 80.
39.	Ayatollahi S, Salmasi Z, Hashemi M, et al. Aptamer-targeted delivery of Bcl-xL shRNA using alkyl modified PAMAM dendrimers into lung cancer cells. International Journal of Biochemistry & Cell Biology, 2017, 92: 210-217.

1. Chen Wanqing, Zheng Rongshou, Baade P D, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
2. Gold L, Janjic N, Jarvis T, et al. Aptamers and the RNA world, past and present. Cold Spring Harb Perspect Biol, 2012, 4(3): 829-841.
3. Mckeague M, Mcconnell E M, Cruz-Toledo J A, et al. Analysis of in vitro aptamer selection parameters. J Mol Evol, 2015, 81(5/6): 150-161.
4. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990, 249(4968): 505-510.
5. Ellington A D, Szostak J W. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346(6287): 818-822.
6. Chen Chan, Zhou Shan, Cai Yongqiang, et al. Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology. Npj Precision Oncology, 2017, 1(1): 37.
7. Pang Xuehui, Cui Cheng, Wan Shuo, et al. Bioapplications of Cell-SELEX-generated aptamers in cancer diagnostics, therapeutics, theranostics and biomarker discovery: a comprehensive review. Cancers (Basel), 2018, 10(2): 47.
8. Shangguan Dihua, Li Ying, Tang Zhiwen, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A, 2006, 103(32): 11838-11843.
9. Quang N N, Miodek A, Cibiel A, et al. Selection of aptamers against whole living cells: from Cell-SELEX to identification of biomarkers. Synthetic Antibodies, 2017, 1575: 253-272.
10. Dou Xiaoqian, Wang Hua, Zhang Jing, et al. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity. Int J Nanomedicine, 2018, 13: 763-776.
11. Hori S I, Herrera A, Rossi J J, et al. Current advances in aptamers for cancer diagnosis and therapy. Cancers (Basel), 2018, 10(1): 9.
12. Catuogno S, Esposito C L, de Franciscis V. Developing aptamers by cell-based SELEX. Methods in Molecular Biology, 2016, 1380: 33.
13. 吴巧艺. 基于 Cell-SELEX 胶质肉瘤与胶质瘤干细胞核酸适配体的筛选及初步应用研究. 福州: 福建医科大学, 2016.
14. Wu Qiaoyi, Wang Yuzhe, Wang Hongyao, et al. DNA aptamers from whole-cell SELEX as new diagnostic agents against glioblastoma multiforme cells. Analyst, 2018, 143(10): 2267-2275.
15. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 2013, 63(1): 11-30.
16. Chen H W, Medley C D, Sefah K, et al. Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem, 2008, 3(6): 991-1001.
17. Kunii T, Ogura S I, Mie Masayasu, et al. Selection of DNA aptamers recognizing small cell lung cancer using living cell-SELEX. Analyst, 2011, 136(7): 1310-1312.
18. Zhao Zilong, Xu Li, Shi Xiaoli, et al. Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. Analyst, 2009, 134(9): 1808-1814.
19. Zamay G S, Kolovskaya O S, Zamay T N, et al. Aptamers selected to postoperative lung adenocarcinoma detect circulating tumor cells in human blood. Molecular Therapy, 2015, 23(9): 1486-1496.
20. He Jinfeng, Tan Wei, Ma Jingping. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer. Future Oncology, 2017, 13(9): 787-797.
21. Zamay G S, Ivanchenko T I, Zamay T N, et al. DNA aptamers for the characterization of histological structure of lung adenocarcinoma. Mol Ther Nucleic Acids, 2017, 6: 150-162.
22. Wu Chunlei, Liu Jianbo, Zhang Pengfei, et al. A recognition-before-labeling strategy for sensitive detection of lung cancer cells with a quantum dot-aptamer complex. Analyst, 2015, 140(17): 6100-6107.
23. 李金明, 章志怀, 彭振元. SELEX 技术筛选特异性结合高转移性肺癌细胞 Anip973 的单链 DNA 适配子. 武汉大学学报: 医学版, 2011, 32(3): 329-333.
24. Wang Qing, Zhou Chenchen, Yang Xiaohai, et al. Probing interactions between human lung adenocarcinoma A549 cell and its aptamers at single-molecule resolution. Journal of Molecular Recognition, 2014, 27(11): 676-682.
25. Nabavinia M S, Charbgoo F, Alibolandi M, et al. Comparison of flow cytometry and ELASA for screening of proper candidate aptamer in Cell-SELEX pool. Appl Biochem Biotechnol, 2018, 184(2): 444-452.
26. Sett A, Borthakur B B, Bora U. Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas. Clinical & Translational Oncology, 2017, 19(8): 976-988.
27. Yuan Baoyin, Jiang Xiaochun, Chen Yuanyuan, et al. Metastatic cancer cell and tissue-specific fluorescence imaging using a new DNA aptamet developed by Cell-SELEX. Talanta, 2017, 170: 56-62.
28. Ott W, Jobst M A, Schoeler C, et al. Single-molecule force spectroscopy on polyproteins and receptor-ligand complexes: The current toolbox. J Struct Biol, 2017, 197(1, SI): 3-12.
29. Liu Lishang, Lu Xiaoling, Zhao Yongxiang. Aptamer-Based strategies for cancer diagnosis and therapy. J Nanosci Nanotechnol, 2016, 16(7): 6611-6621.
30. Mackey D, Kelly E, Nooney R. Modelling random antibody adsorption and immunoassay activity. Mathematical Biosciences and Engineering, 2016, 13(6, SI): 1159-1168.
31. Yin Meili, Li Zhenhua, Liu Zhen, et al. Photosensitizer-incorporated G-quadruplex DNA-functionalized magnetofluorescent nanoparticles for targeted magnetic resonance/fluorescence multimodal imaging and subsequent photodynamic therapy of cancer. Chemical Communications, 2012, 48(52): 6556-6558.
32. Jin Cheng, Qiu Liping, Li Jin, et al. Cancer biomarker discovery using DNA aptamers. Analyst, 2016, 141(2): 461-466.
33. Gold L, Ayers D, Bertino J, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One, 2010, 5(12): e15004.
34. Havel L S, Kline E R, Salgueiro A M, et al. Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity. Oncogene, 2015, 34(15): 1979-1990.
35. Almasi F, Gargari S M, Bitaraf F, et al. Development of a single stranded DNA aptamer as a molecular probe for LNCap cells using Cell-SELEX. Avicenna J Med Biotechnol, 2016, 8(3): 104-111.
36. Lai Weiyun, Wang Weiya, Chang Y C, et al. Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras. Biomaterials, 2014, 35(9): 2905-2914.
37. Perepelyuk M, Sacko K, Thangavel K, et al. Evaluation of MUC1-aptamer functionalized hybrid nanoparticles for targeted delivery of miRNA-29b to non-small cell lung cancer. Molecular Pharmaceutics, 2018, 15(3): 985-993.
38. Morita Y, Leslie M, Kameyama H, et al. Aptamer therapeutics in cancer: current and future. Cancers (Basel), 2018, 10(3): 80.
39. Ayatollahi S, Salmasi Z, Hashemi M, et al. Aptamer-targeted delivery of Bcl-xL shRNA using alkyl modified PAMAM dendrimers into lung cancer cells. International Journal of Biochemistry & Cell Biology, 2017, 92: 210-217.

Previous Article
Biomechanical research progress on sex differences of abdominal aortic aneurysm
Next Article
Applications of generative adversarial networks in medical image processing

Journal of Biomedical Engineering

Screening of nucleic acid aptamer of lung cancer cells based on cell exponential enrichment ligand system evolution and its application in tumor diagnosis and treatment

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content